In-vitro fertilization (IVF) Market size, share, Growth & Trends Analysis Report by Types of cycle (Fresh Cycle (Non-Donor), Thawed IVF Cycle (Non-Donor) and Donor Egg IVF Cycle) by Application (Fertility Clinics, Hospitals, Surgical Centers and Clinical Research Institutes) and Region-Market Intelligence & Forecast, 2019-2026
Date: Dec-2019 | Id: MACRC-1185 | Geographical Scope: Global | Publisher: MACRC
In-vitro fertilization (IVF) Market size, share, Growth & Trends Analysis Report by Types of cycle (Fresh Cycle (Non-Donor), Thawed IVF Cycle (Non-Donor) and Donor Egg IVF Cycle) by Application (Fertility Clinics, Hospitals, Surgical Centers and Clinical Research Institutes) and Region-Market Intelligence & Forecast, 2019-2026.
“Global In-vitro fertilization (IVF) Market was valued at USD 15.21 Billion in the year 2017 and is expected to reach approximately USD 36.15 Billion by 2026, at CAGR 10.1% from 2019 to 2026.”
Introduction
In-vitro fertilization (IVF) is series of procedure used to help with fertility or prevent genetic problems and assist with the conception of a child. IVF works by using the combination of medicines and surgical procedures in order to help sperm fertilize an egg, and help the fertilized egg implant in uterus. The In-vitro fertilization (IVF) market is segmented on the basis of types of cycle and application. Types of cycle wise the market is divided fresh cycle (Non-Donor), thawed IVF cycle (Non-Donor) and donor egg IVF Cycle. Among these types of cycle, the fresh IVF cycles (non-donor) has dominated the market share in terms of revenue. The fresh embryo IVF cycle begins with the ovarian stimulation and followed by retrieval of all eggs from the patient. These eggs are reinserted to create an embryo and then embryos are transferred back in the patient. Applications of In-vitro fertilization (IVF) are fertility clinics, hospitals, surgical centers and clinical research institutes. Fertility clinics provide technologically advanced IVF treatments toward patients having fertility problems. Therefore, having wide range of fertility treatments under one roof coupled with government reimbursements is anticipated to drive the growth of fertility clinic segment.
Market Dynamics
Major factors to drive the growth of IVF market are declining fertility rate and increasing incidences of male and female infertility. Ability to prevent the transfer of genetic disease during IVF treatment is also expected to surge the demand of this market. However, high cost and low success rate of the IVF treatment is restraining the growth of IVF market. Nonetheless, availability of supportive government funding is impelling the demand of IVF market. In addition, in order to spur the demand of IVF, researchers have introduced several such as assisted hatching, egg/sperm freezing, verification, mini IVF, three-parent IVF, Percutaneous Epidydimal Sperm Aspiration and Testicular Sperm Extraction (PESA and TESE), and genetic diagnosis, are especially used.
Geographical Outlook
The global In-vitro fertilization (IVF) market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Geographically, Asia Pacific has accounted for the largest market share of the IVF market in terms of revenue in 2017 due to the large number of population, low cost treatment as compared to developed regions, and technological advancement. Japan, China, and India were the major market share contributing countries for IVF market. North America is expected to fuel the growth of IVF market in coming years owing to presence of favorable reimbursement framework. The U.S Department of Defense has invested USD 50 million 5 years plan for sperm/egg freezing coverage. Moreover, advanced technology coupled with number of new clinics to offer better fertility success rates will fascinate the demand of IVF market in North America region.
Market Segmentation
On the Basis of Types of cycle
Some of the key players operating in the global In-vitro fertilization (IVF) market are Irvine Scientific, CooperSurgical, Inc, Vitrolife AB, Cook Medical, Inc., Kitazato Corporation, Genea Biomedx, OvaScience, EMD Serono, Inc. , Progyny, Inc.,Boston IVF and others
Key questions addresses by the report:
“Global In-vitro fertilization (IVF) Market was valued at USD 15.21 Billion in the year 2017 and is expected to reach approximately USD 36.15 Billion by 2026, at CAGR 10.1% from 2019 to 2026.”
Introduction
In-vitro fertilization (IVF) is series of procedure used to help with fertility or prevent genetic problems and assist with the conception of a child. IVF works by using the combination of medicines and surgical procedures in order to help sperm fertilize an egg, and help the fertilized egg implant in uterus. The In-vitro fertilization (IVF) market is segmented on the basis of types of cycle and application. Types of cycle wise the market is divided fresh cycle (Non-Donor), thawed IVF cycle (Non-Donor) and donor egg IVF Cycle. Among these types of cycle, the fresh IVF cycles (non-donor) has dominated the market share in terms of revenue. The fresh embryo IVF cycle begins with the ovarian stimulation and followed by retrieval of all eggs from the patient. These eggs are reinserted to create an embryo and then embryos are transferred back in the patient. Applications of In-vitro fertilization (IVF) are fertility clinics, hospitals, surgical centers and clinical research institutes. Fertility clinics provide technologically advanced IVF treatments toward patients having fertility problems. Therefore, having wide range of fertility treatments under one roof coupled with government reimbursements is anticipated to drive the growth of fertility clinic segment.
Market Dynamics
Major factors to drive the growth of IVF market are declining fertility rate and increasing incidences of male and female infertility. Ability to prevent the transfer of genetic disease during IVF treatment is also expected to surge the demand of this market. However, high cost and low success rate of the IVF treatment is restraining the growth of IVF market. Nonetheless, availability of supportive government funding is impelling the demand of IVF market. In addition, in order to spur the demand of IVF, researchers have introduced several such as assisted hatching, egg/sperm freezing, verification, mini IVF, three-parent IVF, Percutaneous Epidydimal Sperm Aspiration and Testicular Sperm Extraction (PESA and TESE), and genetic diagnosis, are especially used.
Geographical Outlook
The global In-vitro fertilization (IVF) market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Geographically, Asia Pacific has accounted for the largest market share of the IVF market in terms of revenue in 2017 due to the large number of population, low cost treatment as compared to developed regions, and technological advancement. Japan, China, and India were the major market share contributing countries for IVF market. North America is expected to fuel the growth of IVF market in coming years owing to presence of favorable reimbursement framework. The U.S Department of Defense has invested USD 50 million 5 years plan for sperm/egg freezing coverage. Moreover, advanced technology coupled with number of new clinics to offer better fertility success rates will fascinate the demand of IVF market in North America region.
Market Segmentation
On the Basis of Types of cycle
- Fresh Cycle (Non-Donor)
- Thawed IVF Cycle (Non-Donor)
- Donor Egg IVF Cycle
- Fertility Clinics
- Hospitals
- Surgical Centers
- Clinical Research Institutes
Some of the key players operating in the global In-vitro fertilization (IVF) market are Irvine Scientific, CooperSurgical, Inc, Vitrolife AB, Cook Medical, Inc., Kitazato Corporation, Genea Biomedx, OvaScience, EMD Serono, Inc. , Progyny, Inc.,Boston IVF and others
Key questions addresses by the report:
- How competitive is the market?
- What are the emerging trends?
- What are the global opportunities in the In-vitro fertilization (IVF) market?
- Who are the major market players in the In-vitro fertilization (IVF) market?
- What are the growth trends and the largest revenue-generating region for In-vitro fertilization (IVF) market?
- Which geographical region is holding major potential for new entrants?
TABLE OF CONTENTS Chapter 1. Methodology and Scope 1.1. Research Methodology 1.2. Research Scope & Assumptions 1.3. List of Data Sources 1.4. List of Abbreviations Chapter 2. Executive Summary 2.1. In-vitro fertilization (IVF) Market - Industry Snapshot 2.2. In-vitro fertilization (IVF) Market Chapter 3. Customer Care BPO Industry Outlook 3.1. Market Segmentation 3.2. Value Chain Analysis 3.3. Market Dynamics 3.3.1. Market driver analysis 3.3.2. Market restraint analysis 3.3.3. Market opportunity analysis 3.4. Penetration & Growth Prospects Mapping 3.5. Industry Analysis - Porter’s Five Forces Analysis 3.6. PESTEL Analysis Chapter 4. In-vitro fertilization (IVF) Market: By Types of cycle (USD Billion) 4.1. Fresh Cycle (Non-Donor) 4.2. Thawed IVF Cycle (Non-Donor) 4.3 Donor Egg IVF Cycle Chapter 5. In-vitro fertilization (IVF) Market: Application (USD Billion) 5.1 Fertility Clinics 5.2 Hospitals 5.3 Surgical Centers 5.4 Clinical Research Institutes Chapter 6. In-vitro fertilization (IVF) Market: Regional Outlook 6.1. In-vitro fertilization (IVF) Market Estimates & Forecasts 6.2. North America 6.2.1. Market estimates and forecasts 6.2.2. Market estimates and forecasts, By Types of cycle 6.2.3. Market estimates and forecasts, By Application 6.2.4. U.S. 6.2.4.1. Market estimates and forecasts 6.2.4.2. Market estimates and forecasts, By Types of cycle 6.2.4.3. Market estimates and forecasts, By Application 6.2.5. Canada 6.2.5.1. Market estimates and forecasts 6.2.5.2. Market estimates and forecasts, By Types of Cycle 6.2.5.3. Market estimates and forecasts, By Application 6.3. Europe 6.3.1. Market estimates and forecasts 6.3.2. Market estimates and forecasts, By Types of cycle 6.3.3. Market estimates and forecasts, By Application 6.3.4. U.K. 6.3.4.1. Market estimates and forecasts 6.3.4.2. Market estimates and forecasts, By Types of cycle 6.3.4.3. Market estimates and forecasts, By Application 6.3.5. Germany 6.3.5.1. Market estimates and forecasts 6.3.5.2. Market estimates and forecasts, By Types of cycle 6.3.5.3. Market estimates and forecasts, By Application 6.3.6. France 6.3.6.1. Market estimates and forecasts 6.3.6.2. Market estimates and forecasts, By Types of cycle 6.3.6.3. Market estimates and forecasts, By Application 6.4. Asia Pacific 6.4.1. Market estimates and forecasts 6.4.2. Market estimates and forecasts, By Types of cycle 6.4.3. Market estimates and forecasts, By Application 6.4.4. China 6.4.4.1. Market estimates and forecasts 6.4.4.2. Market estimates and forecasts, By Types of cycle 6.4.4.3. Market estimates and forecasts, By Application 6.4.5. India 6.4.5.1. Market estimates and forecasts 6.4.5.2. Market estimates and forecasts, By Types of cycle 6.4.5.3. Market estimates and forecasts, By Application 6.4.6. Japan 6.4.6.1. Market estimates and forecasts 6.4.6.2. Market estimates and forecasts, By Types of cycle 6.4.6.3. Market estimates and forecasts, By Application 6.4.7. Singapore 6.4.7.1. Market estimates and forecasts 6.4.7.2. Market estimates and forecasts, By Types of cycle 6.4.7.3. Market estimates and forecasts, By Application 6.5. Latin America 6.5.1. Market estimates and forecasts 6.5.2. Market estimates and forecasts, By Types of cycle 6.5.3. Market estimates and forecasts, By Application 6.5.4. Brazil 6.5.4.1. Market estimates and forecasts 6.5.4.2. Market estimates and forecasts, By Types of cycle 6.5.4.3. Market estimates and forecasts, By Application 6.5.5. Mexico 6.5.5.1. Market estimates and forecasts 6.5.5.2. Market estimates and forecasts, By Types of cycle 6.5.5.3. Market estimates and forecasts, By Application 6.6. Middle East & Africa 6.6.1. Market estimates and forecasts 6.6.2. Market estimates and forecasts, By Types of cycle 6.6.3. Market estimates and forecasts, By Application Chapter 7. Competitive Landscape 7.1. Irvine Scientific 7.1.1. Company overview 7.1.2. Financial performance 7.1.3. Product benchmarking 7.1.4. Recent developments 7.2. CooperSurgical, Inc. 7.2.1. Company overview 7.2.2. Financial performance 7.2.3. Product benchmarking 7.2.4. Recent developments 7.3. Vitrolife AB 7.3.1. Company overview 7.3.2. Financial performance 7.3.3. Product benchmarking 7.3.4. Recent developments 7.4. Cook Medical, Inc. 7.4.1. Company overview 7.4.2. Financial performance 7.4.3. Product benchmarking 7.4.4. Recent developments 7.5 Genea Biomedx 7.5.1. Company overview 7.5.2. Financial performance 7.5.3. Product benchmarking 7.5.4. Recent developments 7.6 Boston IVF 7.6.1. Company overview 7.6.2. Financial performance 7.6.3. Product benchmarking 7.6.4. Recent developments 7.7. Kitazato Corporation 7.7.1. Company overview 7.7.2. Financial performance 7.7.3. Product benchmarking 7.7.4. Recent developments 7.8 OvaScience 7.8.1. Company overview 7.8.2. Financial performance 7.8.3. Product benchmarking 7.8.4. Recent developments 7.9 EMD Serono, Inc. 7.9.1. Company overview 7.9.2. Financial performance 7.9.3. Product benchmarking 7.9.4. Recent developments 7.10 Progyny, Inc. 7.10.1. Company overview 7.10.2. Financial performance 7.10.3. Product benchmarking 7.10.4. Recent developments
Related reports
Non-Hodgkin Lymphoma Therapeutics Market
$2000-$6000
Acrylic Teeth Market
$3600-$7000